10-K: Pluri Inc. Faces Financial Hurdles Amidst R&D Expansion

Pluri Inc.'s 2026 10-K filing reveals continued operational losses and a critical going concern warning from auditors, even as the company advances its cell therapy, FoodTech, and CDMO initiatives.

Summary

• Pluri Inc. reported revenues of $1,016,000 for the year ended June 30, 2026, a decrease from $1,336,000 in the prior year, primarily due to lower CDMO and FoodTech project activity.
• Research and development expenses increased by 17% to $15,092,000, while general and administrative expenses rose slightly to $10,299,000.
• The company incurred a net loss of $25,369,000 for the year ended June 30, 2026, an increase from $23,250,000 in the prior year.
• As of June 30, 2026, Pluri Inc. had a working capital deficit of $23,989,000 and an accumulated deficit of $466,876,000.
• The company's cash balance was $8,851,000, with management estimating sufficient resources for less than three months of operations, raising substantial doubt about its ability to continue as a going concern.
• Discussions with the European Investment Bank (EIB) regarding a $20 million loan due June 1, 2026, are ongoing, with a potential sale of the loan to a third party, possibly a related party, under consideration.
• Pluri Inc. received a Nasdaq deficiency letter on July 7, 2026, for failing to meet the minimum market value of listed securities requirement and has until January 4, 2027, to regain compliance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's ongoing financial struggles, substantial accumulated deficit, and the auditor's going concern warning, despite progress in its various business segments.

Positives

• Continued development and progress in Human Health and Longevity, including PLX-PAD and PLX-R18 cell therapy candidates.
• Advancements in FoodTech and Bio-Farming, with subsidiaries Coffeesai (cultivated coffee) and Kokomodo (cell-cultured cacao) progressing.
• Expansion of PluriCDMO services, leveraging GMP manufacturing expertise.
• ISO 13485:2016 certification received by Pluri Biotech, enhancing quality infrastructure for medical device manufacturing.
• Successful acquisition of Fishway BV by Ever After Foods to expand research capabilities and European presence.
• Ongoing collaborations and grant funding from entities like the Israel Innovation Authority (IIA) and Horizon Europe.
• The company is actively pursuing options to regain compliance with Nasdaq listing requirements.

Negatives

• Substantial accumulated deficit of $466,876,000 as of June 30, 2026.
• Auditor's report includes an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• Cash balance of $8,851,000 is estimated to be sufficient for less than three months of operations.
• Net loss increased to $25,369,000 for the fiscal year ended June 30, 2026.
• Received a Nasdaq deficiency letter for failing to meet market value requirements, with a deadline to regain compliance.
• Ongoing discussions and uncertainty surrounding the repayment of the $20 million EIB loan, which became due on June 1, 2026.
• Revenues decreased to $1,016,000 in fiscal year 2026 compared to $1,336,000 in fiscal year 2025.

Risks

• The company has a history of losses and has not generated significant revenues to date, with expectations of future losses and no significant or steady revenues in the immediate future.
• The company may need to raise additional capital, which could be costly, difficult to obtain, and dilute shareholders' ownership interests.
• The auditor's report raises substantial doubt about the company's ability to continue as a going concern.
• Potential claims from larger competitors regarding intellectual property rights.
• Inherent risks in manufacturing cell-based products, including meeting regulatory standards.
• Failure to obtain and maintain intellectual property protection could allow others to utilize the company's IP.
• Exposure to global and local risks due to international operations, including currency exchange rate fluctuations.
• The company could fail to regain compliance with Nasdaq Listing Rules, potentially leading to delisting.

Future Outlook

The company anticipates needing additional liquidity to support commercialization and R&D activities, as near-term revenues are not expected to exceed operating costs. Management estimates having sufficient resources for less than three months, raising substantial doubt about its ability to continue as a going concern. Success is dependent on obtaining additional capital, generating revenues, resolving the EIB loan, and securing other funding sources.

Management Comments

• Management estimates having sufficient resources to meet operating obligations for a period of less than three months from the issuance date of the consolidated financial statements, raising substantial doubt about the company's ability to continue as a going concern.
• The company is addressing liquidity issues by implementing initiatives to allow the continuation of its activities.
• The company intends to take appropriate actions to regain compliance with Nasdaq listing requirements.

Industry Context

StockSavvy.ai notes that Pluri Inc. operates in the highly competitive and rapidly evolving fields of regenerative medicine, cell therapy, and FoodTech. The company's focus on a proprietary 3D cell expansion platform positions it within a sector characterized by significant R&D investment and regulatory hurdles, similar to many other biotechnology firms.

Comparison to Industry Standards

• The regenerative medicine field has 1,806 active cell and gene therapy developers worldwide, with 1,031 developing cell therapies, indicating a crowded and competitive landscape.
• In the global market (excluding China), approximately 20 allogeneic CAR-T therapy products for solid tumors have advanced into clinical stages, highlighting the advanced stage of some competitors.
• The company competes with large service providers like Lonza Group AG, AGC Biologics A/S, and Charles River Laboratories International, Inc. in the CDMO services sector.
• In the cell-cultured coffee market, competitors include California Cultured, Inc., Food Brewer AG, Another Food Pte. Ltd., and Atomo Foods, Inc.
• In the cell-cultured cacao market, competitors include Celleste Bio Ltd., California Cultured, Inc., and Food Brewer AG.

Legal Proceedings

• None.

Related Party Transactions

• The Kokomodo Transaction involved the purchase of equity from Chutzpah Holdings Ltd. and Plantae, entities controlled by director Alexandre Weinstein.
• Securities Purchase Agreements (First and Second Offerings) and an Advance Subscription Agreement were entered into with Chutzpah Holdings LP, an entity beneficially owned by director Alexandre Weinstein.
• Director Alexandre Weinstein was appointed to the Board effective February 5, 2025, in connection with a securities purchase agreement.

Stakeholder Impact

• Shareholders may experience dilution due to potential future capital raises.
• Shareholders face the risk of share price volatility and potential loss of investment due to the company's financial condition and Nasdaq compliance issues.
• Creditors and lenders (like EIB) face uncertainty regarding loan repayment.
• Employees may be impacted by cost-reduction plans, including potential headcount reductions.

Next Steps

• Regain compliance with Nasdaq Listing Rules by January 4, 2027.
• Reach a resolution with the EIB regarding the outstanding loan, potentially involving a sale to a third party and subsequent settlement or equity conversion.
• Continue development and commercialization efforts in Human Health and Longevity, FoodTech, and CDMO segments.
• Seek additional capital to fund operations and development activities.

Key Dates

Recommendation

The company's severe liquidity constraints, auditor's going concern warning, Nasdaq compliance issues, and increasing net losses present significant risks. While there is ongoing development in key areas, the immediate financial challenges and uncertainty surrounding the EIB loan repayment outweigh the potential long-term benefits for investors at this juncture.

Keywords

cell therapy, regenerative medicine, biotechnology, FoodTech, CDMO, cultivated meat, 3D cell expansion, PLX cells